– Reuters Citing NBC
Goldman Sachs Maintains Buy on Cytek Biosciences, Lowers Price Target to $14
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and lowers the price target from $16 to $14.
Related Posts
Maxim Group Initiates Coverage On Charge Enterprises with Buy Rating, Announces Price Target of $8
Maxim Group analyst Tate Sullivan initiates coverage on Charge Enterprises (NASDAQ:CRGE) with a Buy rating and announces Price Target of $8.
Lithia Motors Buys Curry Honda In Georgia And Jeep Volume Dealer In California
Lithia Motors Inc (NYSE:LAD) has acquired Curry Honda, located in Chamblee, Georgia, for an undisclosed sum. The addition is Lithia…
Stifel Maintains Hold on Okta, Lowers Price Target to $195
Stifel analyst Adam Borg maintains Okta (NASDAQ:OKTA) with a Hold and lowers the price target from $200 to $195.